Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

Investing.com -- Metsera Inc. (NASDAQ:MTSR) stock tumbled as much as 16% to $70.15 in premarket trading Monday after Novo Nordisk A/S (NYSE:NVO) abandoned its pursuit of the US weight-loss drug ...

Pfizer (PFE) shares have seen some moderate movement lately, offering investors a chance to reconsider the company’s ...

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and ...

Compared to ABBV, PFE's latest dividend declarations and earnings report reveal growth pressure, high payout ratios, and ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...